(AMLX) Amylyx Pharmaceuticals - Performance 201.1% in 12m
Compare AMLX with Indices, Sectors and Commodities and Bonds. Who performs better in which timeframe?
Performance Rating
-36.49%
#87 in Group
Rel. Strength
98.58%
#115 in Universe
Total Return 12m
201.12%
#6 in Group
Total Return 5y
-70.34%
#107 in Group
P/E -
(?) Percentile in Group
P/E Forward 2.77
6th Percentile in Group
PEG -
(?) Percentile in Group
FCF Yield -
(?) Percentile in Group
12m Total Return: AMLX (201.1%) vs XLV (0.3%)

5y Drawdown (Underwater) Chart

Top Performers in Pharmaceuticals
Overall best picks of Peer Group Selected by proven GARP Predictive Metrics, sorted by Growth Rating
Symbol | 1m | 12m | 5y | P/E | P/E Forward | PEG | EPS Stability |
EPS CAGR |
---|---|---|---|---|---|---|---|---|
CORT NASDAQ Corcept Therapeutics |
23% | 223% | 432% | 50.6 | 37.7 | 0.61 | 61.4% | 10.7% |
LLY NYSE Eli Lilly |
3.78% | 22.8% | 483% | 71.9 | 36.8 | 1.22 | 40.3% | 34.5% |
NVS NYSE Novartis |
1.59% | 17.3% | 62% | 18.9 | 13.6 | 1.3 | 36.2% | 11.6% |
SFZN SW Siegfried Holding |
-0.06% | 6.99% | 104% | 24.1 | 22.1 | 1.41 | 66.7% | 72.5% |
SUPN NASDAQ Supernus Pharmaceuticals |
-2.51% | 9.93% | 64.6% | 24 | 20.2 | 1.47 | -20.8% | -17% |
NOVN SW Novartis |
-5.46% | 6.5% | 35.4% | 18.8 | 13.5 | 1.29 | 36.2% | 11.2% |
SOBI ST Swedish Orphan Biovitrum |
-4.14% | -1.14% | 45.8% | 23.6 | 19.5 | 1.5 | 11.8% | 14.7% |
SAN PA Sanofi |
-11% | 4.99% | 19.7% | 21.2 | 11 | 0.88 | -22.1% | -24.8% |
Performance Comparison: AMLX vs XLV vs S&P 500
XLV (Health Care Sector SPDR ETF) is the Sector Benchmark for AMLX
Total Return (including Dividends) | AMLX | XLV | S&P 500 |
---|---|---|---|
1 Month | 41.80% | -4.97% | -4.31% |
3 Months | 53.58% | -6.08% | -7.85% |
12 Months | 201.12% | 0.26% | 10.76% |
5 Years | -70.34% | 47.01% | 106.31% |
Trend Score (consistency of price movement) | AMLX | XLV | S&P 500 |
1 Month | 71.3% | -54.4% | -35.6% |
3 Months | 45.2% | -66.1% | -89.7% |
12 Months | 73.5% | -12% | 58.3% |
5 Years | -69.3% | 90% | 84.2% |
Relative Strength (compared with Indexes) | Rank in Peer Group | vs. XLV | vs. S&P 500 |
1 Month | #4 | 49.2% | 48.2% |
3 Month | #7 | 63.5% | 66.7% |
12 Month | #5 | 200% | 172% |
5 Years | #101 | -72.6% | -76.0% |
FAQs
Does AMLX Amylyx Pharmaceuticals outperforms the market?
Yes,
over the last 12 months AMLX made 201.12%, while its related Sector, the Health Care Sector SPDR (XLV) made 0.26%.
Over the last 3 months AMLX made 53.58%, while XLV made -6.08%.
Over the last 3 months AMLX made 53.58%, while XLV made -6.08%.
Performance Comparison AMLX vs Indeces and Sectors
AMLX vs. Indices AMLX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
US S&P 500 | SPY | 19.6% | 46.1% | 5.24% | 190% |
US NASDAQ 100 | QQQ | 17.6% | 46.0% | 5.24% | 189% |
US Dow Jones Industrial 30 | DIA | 21.6% | 47.6% | 4.98% | 194% |
German DAX 40 | DAX | 22.2% | 45.6% | -13.2% | 178% |
Shanghai Shenzhen CSI 300 | CSI 300 | 26.1% | 45.3% | 6.66% | 193% |
Hongkong Hang Seng | HSI | 21.8% | 44.7% | 3.37% | 187% |
India NIFTY 50 | INDA | 27.0% | 40.2% | 3.64% | 199% |
Brasil Bovespa | EWZ | 19.8% | 39.8% | 0.74% | 207% |
AMLX vs. Sectors AMLX is Over or Underperforming
Symbol | 1w | 1m | 6m | 12m | |
---|---|---|---|---|---|
Communication Services | XLC | 19.7% | 47.4% | -3.50% | 179% |
Consumer Discretionary | XLY | 17.2% | 45.8% | 2.08% | 187% |
Consumer Staples | XLP | 27.0% | 39.1% | -0.08% | 192% |
Energy | XLE | 22.9% | 53.4% | 7.67% | 213% |
Financial | XLF | 21.5% | 46.6% | -2.86% | 182% |
Health Care | XLV | 22.6% | 46.8% | 7.25% | 201% |
Industrial | XLI | 21.4% | 45.9% | 4.89% | 194% |
Materials | XLB | 22.8% | 46.3% | 12.1% | 206% |
Real Estate | XLRE | 24.4% | 43.7% | 7.39% | 186% |
Technology | XLK | 15.8% | 46.3% | 10.1% | 195% |
Utilities | XLU | 23.7% | 40.1% | 2.14% | 181% |
Aerospace & Defense | XAR | 20.0% | 42.1% | -6.03% | 174% |
Biotech | XBI | 20.4% | 49.6% | 18.3% | 203% |
Homebuilder | XHB | 21.3% | 47.8% | 20.2% | 209% |
Retail | XRT | 22.4% | 44.7% | 9.36% | 205% |